- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02640716
Cog-VACCINE: Cognitive Training in Patients With Vascular Cognitive Impairment, no Dementia (Cog-VACCINE)
The Cog-VACCINE Study: a Randomized Controlled Clinical Trial to Evaluate the Effect of Cognitive Training in Patients With Vascular Cognitive Impairment, no Dementia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background:
Vascular cognitive impairment no dementia (VCIND) refers to cognitive deficits associated with underlying vascular causes which fall short of a dementia diagnosis. Because of its high prevalence and high progression to dementia, interest in VCIND has greatly expanded in recent years. Although it has been widely recognized that early intervention of VCIND holds the potential to delay or even reverse the cognitive impairment, no treatment is available yet. Executive dysfunction is the characteristic impairment in subcortical VCIND, and cognitive training significantly improved executive and other aspects of cognitive function in health older adults and patients with cognitive impairment. Whether and how cognitive training improves cognitive function in patients with VCIND remains largely unknown.
Objectives:
The primary objective of this double-blinded, randomized RCT is to assess whether internet-based cognitive training in patients with subcortical VCIND improves their cognitive abilities. The second objective is to evaluate the effect of cognitive training on neural plasticity, including brain activation and white matter integrity, which are assessed by functional and structural MRI. Finally, possible genetic and plasma biomarkers related to a positive effect or lack of effect of the training will be examined.
Patients and Methods:
The proposed study is a three-center, double-blinded, randomized controlled trial that will include 60 patients diagnosed with VCIND from the neurology clinics at Beijing Friendship hospital, Xuan Wu hospital, and geriatric clinic at Fu Xing hospital, Capital Medical University. The patients will be randomized to either a training or a control group. The intervention is internet-based cognitive training performed for 30 minutes over 35 sessions. Neuropsychological assessment and functional magnetic resonance imaging (MRI) will be performed before and 7 weeks after training.
Relevance:
Currently there is no known treatment available for VCIND. The proposed study is to determine the efficacy of cognitive training in patients with VCIND. Secondly, using functional and structural MRI, this study is to reveal the potential mechanism underlying cognitive training.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100050
- Beijing Friendship Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Literate Han Chinese, aged 50-78 years, with a consistent caregiver who accompanies the subject at least 4 days a week;
- Complaint and/or informant report of cognitive impairment involving memory and/or other cognitive domains lasting for at least 3 months;
- Neither normal nor demented according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, with a clinical dementia rating (CDR) ≥ 0.5 on at least one domain and global score ≤ 0.5; a Mini-Mental State Examination (MMSE) score ≥ 20 (primary school) or ≥ 24 (junior school or above);
- Normal or slightly impaired activities of daily living as defined by a total score of ≤ 1.5 on the three functional CDR domains (home and hobbies, community affairs, and personal care).
The MRI entry criteria are as follows:
- Multiple (≥ 3) supratentorial subcortical small infarcts (3-20 mm in diameter), with/without white matter lesions (WML) of any degree; or moderate to severe WML (score ≥ 2 according to the Fazekas rating scale) with/without small infarct;
- Absence of cortical and watershed infarcts, hemorrhages, hydrocephalus, and WMLs with specific causes (e.g., multiple sclerosis);
- No hippocampal or entorhinal cortex atrophy (score 0 according to the medial temporal lobe atrophy scale of Scheltens).
Exclusion Criteria:
- severe aphasia, physical disabilities, or any other factor that may preclude completion of neuropsychological testing;
- disorders other than subcortical VCIND that may affect cognition;
- a Hamilton depression scale (HAMD) score >17 or schizophrenia;
- new strokes within 3 months before baseline;
- inherited or inflammatory small vessel disease;
- clinically significant gastrointestinal, renal, hepatic, respiratory, infectious, endocrine, or cardiovascular system disease;
- cancer, alcoholism, drug addiction;
- use of medications that may affect cognitive functioning, including tranquilizers, anti-anxiolytics, hypnotics, nootropics, and cholinomimetic agents;
- inability to undergo a brain MRI.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: training group
Intervention: Multi-domain adaptive internet-based training program, including processing speed, attention, long-term memory, working memory, flexibility, calculation, and problem solving.
5 x 30 minutes per week, for 7 weeks.
|
The cognitive training will be a multi-domain adaptive training program, including processing speed, attention, long-term memory, working memory, flexibility, calculation, and problem solving.
Specific training paradigms include a time perception task, visual search task, attention blink, delayed mapping task, attention span task, Go-No go task, Stroop task, task switching, and name-face match task, among others.
To maintain task difficulty, the tasks will be grouped based on the task difficulty in each domain.
Furthermore, each task will have various difficulty levels.
|
Placebo Comparator: control group
Intervention: placebo program: a fixed, primary difficulty level task.
5 x 30 minutes per week, for 7 weeks.
|
For the control group, tasks for processing speed and attention are included.
Importantly, a fixed, primary difficulty level for all participants in the control group is set.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Estimated Mean Change of the Montreal Cognitive Assessment (MoCA)
Time Frame: Baseline and 7 weeks
|
The study uses MoCA to assess changes in the global cognitive function after an intervention of cognitive training. Baseline and 7-week were the two relevant time points used in the calculation. The score of MoCA ranges from 0 to 30, and higher scores mean a better outcome. |
Baseline and 7 weeks
|
Estimated Mean Change of the Trail Making Test (TMT) B-A
Time Frame: Baseline and 7 weeks
|
The Trail Making Test is a commonly used neuropsychological test of visual attention and task-switching.
In two timed tasks, subjects are asked to first connect numbers (Test A), then alternating numbers and letters (Test B), in sequential order as quickly as possible.
Completion times, relating to cognitive processing speed and executive function (respectively) are represented as a difference (B-A).
The Trail Making Test is a commonly used neuropsychological test of visual attention and task-switching.
In two timed tasks, subjects are asked to first connect numbers (Test A), then alternating numbers and letters (Test B), in sequential order as quickly as possible.
Completion times, relating to cognitive processing speed and executive function (respectively) are represented as a difference (B-A).
The change from baseline at week 7 in the B-A difference is reported as a primar
|
Baseline and 7 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Estimated Mean Changes in Left Hippocampal Volume
Time Frame: Baseline and 7 weeks
|
The left hippocampal volume on structural Magnetic Resonance Imaging (MRI) was measured by voxel-based morphometrics.
The estimated mean changes in left hippocampal volume from baseline at week 7 is reported.
|
Baseline and 7 weeks
|
Estimated Mean Change in Right Hippocampal Volume
Time Frame: Baseline and 7 weeks
|
The right hippocampal volume on structural Magnetic Resonance Imaging (MRI) was measured by voxel-based morphometrics.
The estimated mean change in right hippocampal volume from baseline at week 7 is reported.
|
Baseline and 7 weeks
|
Estimated Mean Change in Brain White Matter Integrity
Time Frame: Baseline and 7 weeks
|
The white matter microstructure was measured by diffusion tensor imaging (DTI) . The whole-brain average fractional anisotropy (FA) was calculated to show brain white matter integrity. The change of whole-brain average FA from baseline at week 7 is reported. Fractional anisotropy (FA) is a scalar value between zero and one that describes the degree of anisotropy of a diffusion process. A value of zero means that diffusion is isotropic, i.e. it is unrestricted (or equally restricted) in all directions. |
Baseline and 7 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Estimated Mean Change of MoCA
Time Frame: Baseline and 6 months
|
The participants will be followed up 6 months after recruitment. The training is not mandatory after 7 weeks, but the training details will be acquired from the online system. The change from baseline at month 6 in the MoCA difference is reported. The score of Moca ranges from 0 to 30, and higher scores mean a better outcome. |
Baseline and 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Yi Tang, M.D., Ph.D., Beijing Friendship Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2015010
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vascular Cognitive Impairment no Dementia
-
Sunnybrook Health Sciences CentreCompletedVascular Cognitive Impairment no DementiaCanada
-
The Second Hospital of Hebei Medical UniversityUnknownVascular Cognitive Impairment no DementiaChina
-
Duke UniversityCompletedCognitive Impairment, no Dementia (CIND)United States
-
Sunnybrook Health Sciences CentreRecruitingMild Cognitive Impairment | Vascular Cognitive ImpairmentCanada
-
Amsterdam UMC, location VUmcUnknownVascular Dementia | Mild Cognitive Impairment (Vascular) | Mild Cognitive Disorder (Vascular)Netherlands
-
BaycrestActive, not recruitingCognitive Change | Mild Cognitive Impairment | Dementia Prevention | Subjective Cognitive ImpairmentCanada
-
Cognito Therapeutics, Inc.Active, not recruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Dementia, Alzheimer Type | Dementia Alzheimers | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Dementia, MildUnited States
-
Dalarna UniversityUppsala University; The Swedish Research CouncilRecruitingDementia | Mild Cognitive Impairment | Dementia, Mixed | Dementia of Alzheimer Type | Subjective Cognitive Impairment | Dementia SenileSweden
-
BaycrestCompletedDementia | Mild Cognitive Impairment | Dementia Prevention | Subjective Cognitive Impairment | Pre-dementiaCanada
-
Leiden University Medical CenterAlzheimer NederlandRecruitingCognitive Impairment | Mild Cognitive Impairment | Cerebral Small Vessel Diseases | Dementia, Vascular | Cognitive Decline | Dementia, MixedNetherlands
Clinical Trials on multi-domain internet-based adaptive training program
-
Xuanwu Hospital, BeijingWuhan University; Beijing Friendship Hospital; First Affiliated Hospital Xi'an... and other collaboratorsRecruitingAmnestic Mild Cognitive ImpairmentChina
-
Kazimierz Wielki UniversityNational Science Centre, Poland; John Paul II Catholic University of Lublin...CompletedAging | Cognitive Decline | Old Age; DementiaPoland
-
Beijing Anzhen HospitalBeijing Wispirit Technology Co., LtdNot yet recruitingHypertension | Mild Cognitive ImpairmentChina
-
First Affiliated Hospital of Zhejiang UniversityUnknownAmnestic Mild Cognitive ImpairmentChina
-
University of Milano BicoccaCompletedAge-related Cognitive DeclineItaly
-
Linkoeping UniversityCompleted
-
Stanford UniversityNational Institute on Aging (NIA)CompletedMild Cognitive ImpairmentUnited States
-
University of Colorado, DenverNational Institute of Mental Health (NIMH)CompletedHIV Infections | Sexually Transmitted DiseasesUnited States
-
Virginia Polytechnic Institute and State UniversityRecruitingAlzheimer Disease | AgingUnited States
-
Posit Science CorporationCompleted